- Home
- ARW vs LEGN Comparison
ARW vs LEGN Comparison
Compare ARW & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARW
- LEGN
- Stock Information
- Founded
- ARW 1935
- LEGN 2014
- Country
- ARW United States
- LEGN United States
- Employees
- ARW N/A
- LEGN N/A
- Industry
- ARW Electronic Components
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ARW Technology
- LEGN Health Care
- Exchange
- ARW Nasdaq
- LEGN Nasdaq
- Market Cap
- ARW 6.7B
- LEGN 6.3B
- IPO Year
- ARW N/A
- LEGN 2020
- Fundamental
- Price
- ARW $111.60
- LEGN $32.05
- Analyst Decision
- ARW Hold
- LEGN Strong Buy
- Analyst Count
- ARW 4
- LEGN 12
- Target Price
- ARW $114.75
- LEGN $70.82
- AVG Volume (30 Days)
- ARW 705.0K
- LEGN 1.4M
- Earning Date
- ARW 10-30-2025
- LEGN 11-12-2025
- Dividend Yield
- ARW N/A
- LEGN N/A
- EPS Growth
- ARW 1.13
- LEGN N/A
- EPS
- ARW 9.07
- LEGN N/A
- Revenue
- ARW $29,389,382,000.00
- LEGN $796,838,000.00
- Revenue This Year
- ARW $10.15
- LEGN $68.68
- Revenue Next Year
- ARW $6.03
- LEGN $48.49
- P/E Ratio
- ARW $12.50
- LEGN N/A
- Revenue Growth
- ARW 3.16
- LEGN 74.75
- 52 Week Low
- ARW $86.50
- LEGN $27.34
- 52 Week High
- ARW $134.74
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- ARW 33.21
- LEGN 44.52
- Support Level
- ARW $106.58
- LEGN $31.60
- Resistance Level
- ARW $123.02
- LEGN $33.39
- Average True Range (ATR)
- ARW 3.62
- LEGN 1.16
- MACD
- ARW -0.79
- LEGN 0.09
- Stochastic Oscillator
- ARW 25.06
- LEGN 18.15
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.